H.R. 9823 — Alzheimer’s Early Detection Act of 2026

This section requires group health plans and issuers of group or individual health insurance coverage to cover Alzheimer’s biomarker testing, defined to include tissue, blood, or biospecimen analysis for early detection, diagnosis, treatment, or monitoring of the disease. Coverage must meet parity standards for financial requirements and treatment limits, provide prior authorization decisions within 72 hours (or 24 hours if urgent), prohibit step therapy, and ensure equitable access. The requirements apply to plan years beginning on or after one year after enactment. It also mandates that states cover such testing under Medicaid in the same manner, effective for calendar quarters beginning on or after one year after enactment.